Matrixyl: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

Matrixyl (Palmitoyl Pentapeptide-4, CAS 214047-00-4) is a lipidated matrix pentapeptide —Pal-KTTKS— derived from a fragment of type I procollagen. In dermatological research models it acts as a matrikine that signals fibroblasts to stimulate extracellular matrix synthesis. Material for research.

Matrixyl is the most widely used trade name for Palmitoyl Pentapeptide-4, a lipidated synthetic peptide whose core sequence corresponds to KTTKS (Lysine-Threonine-Threonine-Lysine-Serine) joined at its N-terminus to a palmitic acid chain (C16). It is identified by CAS number 214047-00-4, the molecular formula C39H75N7O10, and an approximate molecular weight of 802.06 g/mol. The usual synonyms in the cosmetic research literature are Pal-KTTKS and Palmitoyl-Lys-Thr-Thr-Lys-Ser. It belongs to the class of "signal" or matrikine skin-care peptides, and is one of the most studied examples of this category within the field of dermocosmetic research.

The conceptual origin of this compound is especially relevant to understanding its mechanism. The KTTKS sequence is not arbitrary: it corresponds to a subfragment of the C-terminal propeptide of type I collagen. During the natural processes of extracellular matrix remodeling, the degradation of collagen releases peptide fragments that act as feedback signals—the so-called matrikines or matrix peptides—capable of informing fibroblasts about the state of the tissue and modulating their biosynthetic activity. KTTKS reproduces one of those endogenous signals. The practical problem of working with the bare pentapeptide is its high polarity and its low ability to cross the lipid barrier of the stratum corneum. To address that limitation in research systems, the molecule is conjugated with palmitic acid: the lipid chain notably increases lipophilicity, improves affinity for membranes and penetration through skin models, and confers greater stability on the conjugate. The result is Pal-KTTKS, an amphipathic molecule with a hydrophilic peptide head and a hydrophobic lipid tail.

From a structural standpoint, the pentapeptide contributes two lysine residues (with positively charged amino groups), two threonine residues, and one serine residue (with hydroxyl groups capable of hydrogen-bond-type interactions), while the palmitoyl acts as a lipid anchor. This architecture is the basis of its behavior in formulations and of its interaction with cell membranes in the experimental models.

The proposed mechanism of action, as described in the in vitro research literature, is that of a "collagen fragment biomimicry" signal. In dermal fibroblast cultures, exposure to Pal-KTTKS has been associated with an increase in the expression and deposition of extracellular matrix components, including type I collagen, type III collagen, fibronectin and, in some works, glycosaminoglycans. The dominant hypothesis is that the peptide mimics the feedback signal that would normally indicate to the fibroblast the need to replenish matrix, thereby activating biosynthesis pathways. It is important to emphasize that the precise molecular target and the exact receptors involved are not fully characterized; most of the effect is described at a functional level (increased matrix synthesis) rather than as the activation of a fully identified specific receptor. Therefore, the mechanism should be understood as a working model supported by phenotypic observations in culture, not as a closed signaling pathway.

As for documented research applications, Matrixyl has been used mainly as a study agent in models of extrinsic and intrinsic skin aging. The experimental systems include fibroblast cultures, reconstructed skin models, and cosmetic studies applied topically. The research rationale is to evaluate whether restoring a matrikine signal can counteract the reduction in collagen synthesis associated with aging and photodamage. It is also studied as a tool to compare strategies for transdermal peptide delivery, precisely because the palmitoylated version was designed to overcome the penetration limitations of the native peptide.

As for the level of evidence, it is best to be honest and precise. Within the universe of cosmetic peptides, Matrixyl is one of those with the most experimental support: there is a consistent body of in vitro work in fibroblasts and several applied cosmetic studies in humans with topical formulations that have reported improvements in roughness parameters and the appearance of fine lines. However, this compound is not an approved drug, nor does it belong to a therapeutic class with regulatory clinical trials; the available human studies are mostly cosmetic, with modest sample sizes, heterogeneous methodologies, and, frequently, funding from the skin-care industry. The reported effects tend to be subtle and dependent on concentration and vehicle. Consequently, the evidence should be classified as preclinical reinforced by limited cosmetic data, and any interpretation of results in a research context should take that gradation into account. Medical-type clinical efficacy or approved therapeutic use must not be inferred.

In the laboratory context, Pal-KTTKS is usually handled as a powder and incorporated into topical vehicles or culture media for the corresponding assays. Its amphipathic character makes solubility and the choice of vehicle relevant experimental variables. All material described in this monograph is intended exclusively for research use and experimental characterization; the information presented here is for scientific and documentary purposes.